Healthcare
Royalty Pharma plc(RPRX)
Live Price
Offline$52.96
-1.38% today
1Y Change
+55.68%
Window
Jun 20, 2025 โ Jun 15, 2026
- Market Cap
- $21.51B
- Revenue Growth
- +5.1%
- EPS Growth
- +20.7%
- Dividend Yield
- 1.8%
Coverage: 248 bars ยท Jun 20, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Royalty Pharma plc (RPRX) is a Healthcare stock with a market cap of $21.51B and listed on NASDAQ. The stock last traded around $52.96 and up 55.7% across the available one-year price window (Jun 20, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +5.1%, EPS growth of +20.7%, a dividend yield of 1.8%. What stands out right now is revenue +5.1%, EPS +20.7%, free cash flow -10.1% with operating margin 65.6% and ROIC 8.9%. The dividend is present but secondary, with a yield around 1.8%. Valuation already assumes a fairly strong business story at P/E 28.1 and price/sales 9.0. Stock Foundry combines RPRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.1% vs +7.6% peer median
Operating Margin
Above sector median
+65.6% vs +19.4% peer median
P/E
Below sector median
28.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 6, 2026 with an EPS surprise of +7.4% and a revenue surprise of +4.9%.
The operating story is still moving forward
Revenue is running at +5.1% and EPS at +20.7%, with operating margin around 65.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 5, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | +7.4% | -1.0% | +5.0% | +8.5% |
2026 Feb 11, 2026 | +13.2% | +1.2% | +1.9% | +3.7% |
2025 Nov 5, 2025 | +17.7% | +0.9% | -2.1% | -3.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RPRX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RPRX Max Drawdown
-7.94%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RPRX and SPY.
Company Overview
Royalty Pharma plc
NASDAQ Global Select
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
- Leadership
- Pablo Legorreta
- IPO Date
- Jun 16, 2020
- Employees
- 75
- Street Address
- 110 East 59th Street
- Mailing
- New York City, NY, 10022
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 883 0200
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 28.1
- EV/EBITDA
- 18.3
- Price/Sales
- 9.0
- Price/Book
- 3.3
Growth
- Revenue
- +5.1%
- EPS
- +20.7%
- Free Cash Flow
- -10.1%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- 65.6%
- Net Margin
- 32.4%
- ROE
- 11.9%
- ROIC
- 8.9%
Balance Sheet
- Debt/Equity
- 1.38
- Current Ratio
- 0.97
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.